rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-3-105-110rpcardio-1121Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯANGIOTENSIN II AND MYOCARDIAL INFARCTIONАНГИОТЕНЗИН II И ИНФАРКТ МИОКАРДАШевченкоО. П.ShevchenkoO. P.

Кафедра кардиологии

Chair of cardiology

ШевченкоА. О.ShevchenkoА. О.

Кафедра кардиологии

Chair of cardiology

Российский государственный медицинский университет, МоскваРоссияRussian State Medical University, MoscowRussian Federation20083001201643105110Copyright © Shevchenko O.P., Shevchenko А.О., 20162016Шевченко О.П., Шевченко А.О.Shevchenko O.P., Shevchenko А.О.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1121

The role of angiotensin II in pathogenesis of cardiovascular diseases is discussed. Angiotensin II participates in development of acute myocardial infarction (MI) in patients with atherosclerosis. It contributes to inflammation of vessel intimae, oxidative stress, cells apoptosis, matrix remodeling, has pro-thrombosis action, promotes MI expansion and post-MI remodeling. Angiotensin converting enzyme (ACE) inhibitors reduce mortality and improve prognosis of patients with acute MI. In patients with ischemic heart disease including patients after MI ACE inhibitors reduce mortality, risk of repeated MI as well as improve quality of life.

Обсуждается роль ангиотензина II в патогенезе сердечно-сосудистых заболеваний. Ангиотензин II участвует в развитии острого инфаркта мио- карда (ИМ) при атеросклерозе. Он способствует воспалению интимы сосудов, вызывает оксидативный стресс, апоптоз клеток, ремоделирование матрикса, обладает протромботическим действием, способствует расширению зоны инфаркта и развитию постинфарктного ремоделирования миокарда. Уменьшение синтеза ангиотензина II под влиянием ингибиторов ангиотензинпревращающего фермента (АПФ) снижает смерт- ность и улучшает отдаленный прогноз у больных острым ИМ. У больных хронической ишемической болезнью сердца, в том числе после ИМ, ингибиторы АПФ также снижают смертность, риск повторного ИМ и улучшают качество жизни.

ангиотензин IIинфаркт миокардаингибиторы АПФлизиноприлangiotensin IImyocardial infarctionACE inhibitorlisinoprilReferencesВебер В.Р., Бритов А.Н. Профилактика и лечение АГ. Великий Новгород: Виконт; 2002.Вебер В.Р., Бритов А.Н. Профилактика и лечение АГ. Великий Новгород: Виконт; 2002.Карпов Ю.А. ИАПФ: от снижения АД до профилактики осложнений и улучшения прогноза. Сердце 2002;1(4):192-4.Карпов Ю.А. ИАПФ: от снижения АД до профилактики осложнений и улучшения прогноза. Сердце 2002;1(4):192-4.Лопатин Ю.М. Антигипертензивные эффекты ингибитора АПФ периндоприла (взгляд с позиции исследования ASCOT-BPLA). Кардиоваск тер профилакт 2006;(3):83-7.Лопатин Ю.М. Антигипертензивные эффекты ингибитора АПФ периндоприла (взгляд с позиции исследования ASCOT-BPLA). Кардиоваск тер профилакт 2006;(3):83-7.Шевченко О.П., Мишнёв О.Д. ИБС. М.: Реафарм; 2005.Шевченко О.П., Мишнёв О.Д. ИБС. М.: Реафарм; 2005.Stone C.K., Uretsky B.F., Linnemeier T.J. et al. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Am J Cardiol 1989;63(9):567–70.Stone C.K., Uretsky B.F., Linnemeier T.J. et al. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Am J Cardiol 1989;63(9):567–70.Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2(4):755–63.Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2(4):755–63.Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259(4):539–44.Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259(4):539–44.Brown E.J. Jr., Chew P.H., MacLean A. et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. Am J Cardiol 1995;75(8):596–600.Brown E.J. Jr., Chew P.H., MacLean A. et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. Am J Cardiol 1995;75(8):596–600.Шевченко О.П., Шевченко А.О. Статины. Ингибиторы ГМГ-КоА- редуктазы. М.: Реафарм; 2003.Шевченко О.П., Шевченко А.О. Статины. Ингибиторы ГМГ-КоА- редуктазы. М.: Реафарм; 2003.McMurray J.J., Young J.B., Dunlap M.E. et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006;151(5):985-8.McMurray J.J., Young J.B., Dunlap M.E. et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006;151(5):985-8.Deedwania P.C. Clinical profile of fosinopril, a novel phosphinic acid ACE inhibitor, for the treatment of heart failure. Heart Failure 1995;11:121-3.Deedwania P.C. Clinical profile of fosinopril, a novel phosphinic acid ACE inhibitor, for the treatment of heart failure. Heart Failure 1995;11:121-3.Uretsky B.F., Shaver J.A., Liang C.S. et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am Heart J 1988;116 (2 Pt 1):480–8.Uretsky B.F., Shaver J.A., Liang C.S. et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am Heart J 1988;116 (2 Pt 1):480–8.Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. М.: Реафарм; 2004.Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. М.: Реафарм; 2004.Шевченко О.П., Праскурничий Е.А., Шевченко А.О. АГ и ожирение. М.: Реа- фарм; 2006.Шевченко О.П., Праскурничий Е.А., Шевченко А.О. АГ и ожирение. М.: Реа- фарм; 2006.Busse R., Fleming I., Hecker M. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy. J Cardiovasc Pharmacol 1993;22(Suppl 5):S31–S36.Busse R., Fleming I., Hecker M. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy. J Cardiovasc Pharmacol 1993;22(Suppl 5):S31–S36.Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83(6):1849–65.Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83(6):1849–65.Spinale F.G., Holzgrefe H.H., Mukherjee R. et al. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. Circulation 1995;92(3):562–78.Spinale F.G., Holzgrefe H.H., Mukherjee R. et al. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. Circulation 1995;92(3):562–78.Taylor K., Patten R.D., Smith J.J. et al. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol 1998;31(5):654–60.Taylor K., Patten R.D., Smith J.J. et al. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol 1998;31(5):654–60.Anvari A., Trel Z., Schmidt A. et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias. Cardiovasc Res 1999;43(4):879–83.Anvari A., Trel Z., Schmidt A. et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias. Cardiovasc Res 1999;43(4):879–83.Ertl G., Kloner R.A., Alexander R.W., Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65(1):40–8.Ertl G., Kloner R.A., Alexander R.W., Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65(1):40–8.Bussman W.D., Micke G., Hildenbrand R., Klepzig H. Jr. Captopril in acute myocardial infarction: beneficial effects on infarct size and arrhythmias. Clin Cardiol 1995;18(8):465–70.Bussman W.D., Micke G., Hildenbrand R., Klepzig H. Jr. Captopril in acute myocardial infarction: beneficial effects on infarct size and arrhythmias. Clin Cardiol 1995;18(8):465–70.Oldroyd K.G., Pye M.P., Ray S.G. et al. Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol 1991;68(8):713–8.Oldroyd K.G., Pye M.P., Ray S.G. et al. Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol 1991;68(8):713–8.Anderson T. Current trials on angiotensin-converting enzyme inhibitors and endothelial dysfunction. Can J Cardiol 1998;14(Suppl D):33D–34D.Anderson T. Current trials on angiotensin-converting enzyme inhibitors and endothelial dysfunction. Can J Cardiol 1998;14(Suppl D):33D–34D.Mancini G.B., Henry G.C., Macaya C. et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94(3):258–65.Mancini G.B., Henry G.C., Macaya C. et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94(3):258–65.Hornig B., Drexler H. Endothelial function and bradykinin in humans. Drugs 1997;54(Suppl 5):42–7.Hornig B., Drexler H. Endothelial function and bradykinin in humans. Drugs 1997;54(Suppl 5):42–7.Taddei S., Virdis A., Ghiadoni L. et al. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998;16(4):447–56.Taddei S., Virdis A., Ghiadoni L. et al. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998;16(4):447–56.Nakamura M., Funakoshi T., Arakawa N. et al. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 1994;24(5):1321–7.Nakamura M., Funakoshi T., Arakawa N. et al. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 1994;24(5):1321–7.Hornig B., Arakawa N., Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998;19(Suppl G):G48– G53.Hornig B., Arakawa N., Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998;19(Suppl G):G48– G53.McKay R.G., Pfeffer M.A., Paternak R.C. et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986;74(4):693–702.McKay R.G., Pfeffer M.A., Paternak R.C. et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986;74(4):693–702.Pfeffer J.M., Pfeffer M.A., Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84–95.Pfeffer J.M., Pfeffer M.A., Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84–95.Weber K.T. Targeting pathological remodeling concepts of cardioprotection and reparation. Circulation 2000;102:1342–5.Weber K.T. Targeting pathological remodeling concepts of cardioprotection and reparation. Circulation 2000;102:1342–5.Alderman M.H., Madhavan S., Ooi W.L. et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324(16):1098–104.Alderman M.H., Madhavan S., Ooi W.L. et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324(16):1098–104.Remme W.J. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy? Drugs 1997;54(Suppl 5):59–70.Remme W.J. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy? Drugs 1997;54(Suppl 5):59–70.Goetz R.M., Holtz J. Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aortae from hypertensive rats: evidence for a causal link. Clin Sci 1999;97(2):165–74.Goetz R.M., Holtz J. Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aortae from hypertensive rats: evidence for a causal link. Clin Sci 1999;97(2):165–74.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429–35.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429–35.CONSENSUS trial group. Effects of enalapril on long-term mortality in severe congestive heart failure. Am J Cardiol 1992;69(1):103-10.CONSENSUS trial group. Effects of enalapril on long-term mortality in severe congestive heart failure. Am J Cardiol 1992;69(1):103-10.Swedberg K., Held P., Kjekshus J. et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327(10):678–80.Swedberg K., Held P., Kjekshus J. et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327(10):678–80.Pfeffer M.A., Braunwald E., Moy L.A. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669–77.Pfeffer M.A., Braunwald E., Moy L.A. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669–77.Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343(8906):1115–22.Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343(8906):1115–22.Pedrazzini G., Santoro E., Latini R. et. al. Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial. Am Heart J 2008;155(2):388-94.Pedrazzini G., Santoro E., Latini R. et. al. Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial. Am Heart J 2008;155(2):388-94.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS- 4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345(8951):669–85.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS- 4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345(8951):669–85.Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-convertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332(2):80–5.Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-convertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332(2):80–5.Ali S.M., Brown E.J. Jr., Nallapati S.R., Alhaddad I.A. Early angiotensin converting enzyme inhibitor therapy after experimental myocardial infarction prevents left ventricular dilation by reducing infarct expansion: a possible mechanism of clinical benefits. Coron Artery Dis 1998;9(12):815–22.Ali S.M., Brown E.J. Jr., Nallapati S.R., Alhaddad I.A. Early angiotensin converting enzyme inhibitor therapy after experimental myocardial infarction prevents left ventricular dilation by reducing infarct expansion: a possible mechanism of clinical benefits. Coron Artery Dis 1998;9(12):815–22.ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97(22):2202–12.ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97(22):2202–12.Schuster E.H., Bulkley B.H. Expansion of transmural myocardial infarction: a pathophysiologic factor in cardiac rupture. Circulation 1979;60:1532–8.Schuster E.H., Bulkley B.H. Expansion of transmural myocardial infarction: a pathophysiologic factor in cardiac rupture. Circulation 1979;60:1532–8.Carstensen S., Bonarjee V.V., Berning J. et al. Effects of early enalapril treatment on global and regional wall motion in acute myocardial infarction. CONSENSUS II Multi Echo Study Group. Am Heart J 1995;129(6):1101–8.Carstensen S., Bonarjee V.V., Berning J. et al. Effects of early enalapril treatment on global and regional wall motion in acute myocardial infarction. CONSENSUS II Multi Echo Study Group. Am Heart J 1995;129(6):1101–8.Edner M., Bonarjee V.V., Nilsen D.W. et al. Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group. Clin Cardiol 1996;19(7):543–8.Edner M., Bonarjee V.V., Nilsen D.W. et al. Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group. Clin Cardiol 1996;19(7):543–8.Bonarjee V.V., Carstensen S., Caidahl K. et al. Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group. Am Heart J 1996;132(1 Pt 1):71–7.Bonarjee V.V., Carstensen S., Caidahl K. et al. Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group. Am Heart J 1996;132(1 Pt 1):71–7.Jugdutt B.I., Schwarz-Michorowski B.L., Khan M.I. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol 1992;19(3):713–21.Jugdutt B.I., Schwarz-Michorowski B.L., Khan M.I. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol 1992;19(3):713–21.Brown E.J. Jr., Swinford R.D., Gadde P., Lillis O. Acute effects of delayed reperfusion on myocardial infarct shape and left ventricular volume: a potential mechanism of additional benefits from thrombolytic therapy. J Am Coll Cardiol 1991;17(7):1641–50.Brown E.J. Jr., Swinford R.D., Gadde P., Lillis O. Acute effects of delayed reperfusion on myocardial infarct shape and left ventricular volume: a potential mechanism of additional benefits from thrombolytic therapy. J Am Coll Cardiol 1991;17(7):1641–50.Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100(23):2312–8.Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100(23):2312–8.Shotan A., Widerhorn J., Hurst A., Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994;96(5):451–6.Shotan A., Widerhorn J., Hurst A., Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994;96(5):451–6.David D., Jallad N., Germino F.W. et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitorassociated cough. Am J Ther 1995;2(10):806–13.David D., Jallad N., Germino F.W. et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitorassociated cough. Am J Ther 1995;2(10):806–13.Rutherford J.D., Pfeffer M.A., Moy L.A. et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90(4):1731–8.Rutherford J.D., Pfeffer M.A., Moy L.A. et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90(4):1731–8.Yusuf S., Pepine C.J., Garces C. et al. Effect of enalapril on MI and unstable angina in patients with low ejection fractions. Lancet 1992;340(8829): 1173–8.Yusuf S., Pepine C.J., Garces C. et al. Effect of enalapril on MI and unstable angina in patients with low ejection fractions. Lancet 1992;340(8829): 1173–8.Pfeffer M.A., Domanski M., Rosenberg Y. et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. Am J Cardiol 1998; 82(3A):25H-30H.Pfeffer M.A., Domanski M., Rosenberg Y. et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. Am J Cardiol 1998; 82(3A):25H-30H.

The authors declare that there are no conflicts of interest present.